2 research outputs found
ADAHELI+: Exploring the fast, dynamic Sun in the X-ray, optical, and near-infrared
Advanced Astronomy for Heliophysics Plus (ADAHELI+) is a project concept for a small solar and
space weather mission with a budget compatible with an European Space Agency (ESA) S-class mission,
including launch, and a fast development cycle. ADAHELI+ was submitted to the European Space Agency
by a European-wide consortium of solar physics research institutes in response to the âCall for a small mission
opportunity for a launch in 2017,â of March 9, 2012. The ADAHELI+ project builds on the heritage of the former
ADAHELI mission, which had successfully completed its phase-A study under the Italian Space Agency 2007
Small Mission Programme, thus proving the soundness and feasibility of its innovative low-budget design.
ADAHELI+ is a solar space mission with two main instruments: ISODY+: an imager, based on FabryâPĂ©rot
interferometers, whose design is optimized to the acquisition of highest cadence, long-duration, multiline spectropolarimetric
images in the visible/near-infrared region of the solar spectrum. XSPO: an x-ray polarimeter for
solar flares in x-rays with energies in the 15 to 35 keV range. ADAHELI+ is capable of performing observations
that cannot be addressed by other currently planned solar space missions, due to their limited telemetry, or by
ground-based facilities, due to the problematic effect of the terrestrial atmospher
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatmentâresistant depression
© 2023 The Authors. Bipolar Disorders published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives. https://creativecommons.org/licenses/by-nc-nd/4.0/Background: Bipolar depression accounts for most of the disease duration in type I and type II bipolar disorder (BD), with few treatment options, often poorly tolerated. Many individuals do not respond to firstâline therapeutic options, resulting in treatmentâresistant bipolar depression (BâTRD). Esketamine, the Sâenantiomer of ketamine, has recently been approved for treatmentâresistant depression (TRD), but no data are available on its use in BâTRD. Objectives: To compare the efficacy of esketamine in two samples of unipolar and bipolar TRD, providing preliminary indications of its effectiveness in BâTRD. Secondary outcomes included the evaluation of the safety and tolerability of esketamine in BâTRD, focusing on the average risk of an affective switch. Methods: Thirtyâfive BâTRD subjects treated with esketamine nasal spray were enrolled and compared with 35 TRD patients. Anamnestic data and psychometric assessments (MontgomeryâAsberg Depression Rating Scale/MADRS, Hamiltonâdepression scale/HAMâD, Hamiltonâanxiety scale/HAMâA) were collected at baseline (T0), at one month (T1), and three months (T2) follow up. Results: A significant reduction in depressive symptoms was found at T1 and T2 compared to T0, with no significant differences in response or remission rates between subjects with BâTRD and TRD. Esketamine showed a greater anxiolytic action in subjects with BâTRD than in those with TRD. Improvement in depressive symptoms was not associated with treatmentâemergent affective switch. Conclusions: Our results supported the effectiveness and tolerability of esketamine in a realâworld population of subjects with BâTRD. The low risk of manic switch in BâTRD patients confirmed the safety of this treatment.Peer reviewe